The New Era of Biologics in Atopic Dermatitis: A Review

被引：14

作者：

Schneider, Simon ^{[1
]}

Li, Linda ^{[1
]}

Zink, Alexander ^{[1
,2
]}

机构：

[1] Tech Univ Munich, Sch Med, Dept Dermatol & Allergy, Munich, Germany

[2] Karolinska Inst, Dept Med Solna, Div Dermatol & Venereol, Stockholm, Sweden

来源：

DERMATOLOGY PRACTICAL & CONCEPTUAL | 2021年 / 11卷 / 04期

关键词：

atopic dermatitis; therapy; biological; dupilumab; ANTIBODY; SKIN; EXPRESSION; DUPILUMAB; RECEPTOR; CELLS; IL-33; TOLERABILITY; CYTOKINE; MODERATE;

D O I：

10.5826/dpc.1104a144

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Atopic dermatitis (AD) is a prevalent inflammatory skin disorder affecting all age and ethnic groups. The age-dependent varying appearance and extent of pruritic lesions are accompanied by distinct individual suffering, highlighting the importance of effective treatment options. Over the past years systemic drugs have considerably extended therapeutic approaches of patients with moderate to severe AD, in particular new biologics, most notably dupilumab has appeared as major breakthrough. In addition to monoclonal blockade of IL-4 and IL-13 pathway, more cytokines have been found to play a substantial role in AD pathogenesis, presenting potential targets for new therapy options.

引用

页数：6

共 37 条

[1] Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis [J].

Beck, Lisa A. ;

Thaci, Diamant ;

Hamilton, Jennifer D. ;

Graham, Neil M. ;

Bieber, Thomas ;

Rocklin, Ross ;

Ming, Jeffrey E. ;

Ren, Haobo ;

Kao, Richard ;

Simpson, Eric ;

Ardeleanu, Marius ;

Weinstein, Steven P. ;

Pirozzi, Gianluca ;

Guttman-Yassky, Emma ;

Suarez-Farinas, Mayte ;

Hager, Melissa D. ;

Stahl, Neil ;

Yancopoulos, George D. ;

Radin, Allen R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :130-139

[2] Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis [J].

Chen, Yi-Ling ;

Gutowska-Owsiak, Danuta ;

Hardman, Clare S. ;

Westmoreland, Melanie ;

MacKenzie, Teena ;

Cifuentes, Liliana ;

Waithe, Dominic ;

Lloyd-Lavery, Antonia ;

Marquette, Allison ;

Londei, Marco ;

Ogg, Graham .

SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (515)

[3] A novel IL-1 family cytokine, IL-33, potently activates human eosinophils [J].

Cherry, W. Brett ;

Yoon, Juhan ;

Barternes, Kathleen R. ;

Iijima, Koji ;

Kita, Hirohito .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2008, 121 (06) :1484-1490

[4] Targeting key proximal drivers of type 2 inflammation in disease [J].

Gandhi, Namita A. ;

Bennett, Brandy L. ;

Graham, Neil M. H. ;

Pirozzi, Gianluca ;

Stahl, Neil ;

Yancopoulos, George D. .

NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (01) :35-50

[5] Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship [J].

Geoghegan, Joan A. ;

Irvine, Alan D. ;

Foster, Timothy J. .

TRENDS IN MICROBIOLOGY, 2018, 26 (06) :484-497

[6] Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis [J].

Grimstad, Oystein ;

Sawanobori, Yasushi ;

Vestergaard, Christian ;

Bilsborough, Janine ;

Olsen, Uffe Bang ;

Gronhoj-Larsen, Christian ;

Matsushima, Kouji .

EXPERIMENTAL DERMATOLOGY, 2009, 18 (01) :35-43

[7] Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis A Phase 2b Randomized Clinical Trial [J].

Guttman-Yassky, Emma ;

Blauvelt, Andrew ;

Eichenfield, Lawrence F. ;

Paller, Amy S. ;

Armstrong, April W. ;

Drew, Janice ;

Gopalan, Ramanan ;

Simpson, Eric L. .

JAMA DERMATOLOGY, 2020, 156 (04) :411-420

[8] GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis [J].

Guttman-Yassky, Emma ;

Pavel, Ana B. ;

Zhou, Lisa ;

Estrada, Yeriel D. ;

Zhang, Ning ;

Xu, Hui ;

Peng, Xiangyu ;

Wen, Huei-Chi ;

Govas, Panayiota ;

Gudi, Girish ;

Vinu, C. A. ;

Fang, Hui ;

Salhi, Yacine ;

Back, Jonathan ;

Reddy, Venkateshwar ;

Bissonnette, Robert ;

Maari, Catherine ;

Grossman, Fred ;

Wolff, Gerhard .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 144 (02) :482-+

[9] Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial [J].

Guttman-Yassky, Emma ;

Brunner, Patrick M. ;

Neumann, Avidan U. ;

Khattri, Saakshi ;

Pavel, Ana B. ;

Malik, Kunal ;

Singer, Giselle K. ;

Baum, Danielle ;

Gilleaudeau, Patricia ;

Sullivan-Whalen, Mary ;

Rose, Sharon ;

On, Shelbi Jim ;

Li, Xuan ;

Fuentes-Duculan, Judilyn ;

Estrada, Yeriel ;

Garcet, Sandra ;

Traidl-Hoffmann, Claudia ;

Krueger, James G. ;

Lebwohl, Mark G. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) :872-+

[10] Regulation of IL-4 Expression in Immunity and Diseases [J].

Ho, I-Cheng ;

Miaw, Shi-Chuen .

REGULATION OF CYTOKINE GENE EXPRESSION IN IMMUNITY AND DISEASES, 2016, 941 :31-77

← 1 2 3 4 →